Navigation Links
UCB and PDL BioPharma Resolve Patent Disputes
Date:2/8/2011

BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL's patents known as the Queen et al. patents.

Under the settlement agreement, PDL provided UCB a covenant not to sue UCB for any royalties regarding UCB's Cimzia product under the Queen patent portfolio in return for a lump sum payment of US$10 million and the mutual resolution of other disputes between the two companies, including two pending patent interferences before the United States Patent and Trademark Office and a patent opposition in the European Patent Office. No additional payments will be owed by UCB to PDL under the Queen patents in respect of Cimzia sales for any indication and the sale of a product in development that may or may not be approved within the term of the Queen patents.

About Cimzia

Cimzia® is a pegylated, humanized TNFa (tumor necrosis factor alpha) antibody fragment. The U.S. Food and Drug Administration has approved Cimzia for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). Cimzia in combination with methotrexate (MTX), is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease modifying antirheumatic drugs including MTX. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia is a registered trademark of UCB.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements, including because UCB or PDL fail to timely fulfill their respective obligations under the settlement agreement. PDL and UCB expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their respective expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
2. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
3. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
4. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
5. Genesis Biopharma to Present at 2011 Biotech Showcase Conference
6. PDL BioPharma to Present at the 29th Annual JP Morgan Healthcare Conference
7. Pharmaceutical Industry Labor-Management Association Applauds Senator Casey (D-PA) for Biopharmaceutical Job Creation Efforts
8. Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer
9. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
11. Sutro Biopharma Secures $36.5 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
(Date:2/16/2017)...  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ) ... that executive management will participate in the RBC Capital ... 2017. Adrian Adams , Chief Executive Officer, will ... local time on Wednesday, February 22, 2017. ... may be accessed from the Investors section of the ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
Breaking Medicine Technology:
(Date:2/19/2017)... CA (PRWEB) , ... February 19, 2017 , ... ProBrand Glitch is a set of ... With ProBrand Glitch users can easily reveal any logo with a glitch reveal in just ... users control over the style and animation of each preset. Use these presets to add ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... ... ... Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, ... , What are the critical reimbursement questions manufacturers should be asking before ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
Breaking Medicine News(10 mins):